Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk
Company has changed auditors in a bid to comply with U.S. law and avoid a potential forced delisting from the Nasdaq Key Takeaways: BeiGene has switched auditors for its New…
RELATED ARTICLES
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
